A Promising Innovative Treatment for ST-Elevation Myocardial Infarction: The Use of C-Reactive Protein Selective...

Area of Science:

• Cardiology
• Biochemistry
• Medical Technology

Background:

• C-reactive protein (CRP) levels correlate with infarct size, left ventricular dysfunction, and mortality in ST-elevation myocardial infarction (STEMI).
• CRP apheresis has demonstrated feasibility, safety, and beneficial effects on infarct size and cardiac function post-STEMI.

Observation:

• A 53-year-old female with anterior STEMI underwent selective CRP apheresis using Spectra-Optia and Pentrasorb CRP-adsorber systems.
• The procedure involved processing 15,600 mL of blood, with a 72% reduction in CRP levels (from 16.4 mg/L to 4.59 mg/L).
• The treatment was well-tolerated, with no adverse effects or significant changes in biochemistry or hemostatic activity.

Findings:

• Selective CRP apheresis effectively reduced CRP plasma levels by 72% in a STEMI patient.
• The procedure was safe and well-tolerated, with no observed complications or adverse events.

Implications:

• Early CRP apheresis is a promising therapeutic strategy for STEMI, potentially reducing infarct size and the incidence of heart failure.
• Further multicenter randomized clinical studies are necessary to fully evaluate the efficacy and safety of CRP apheresis in STEMI treatment.